Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:51 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML
NCT00003407 · Rush University Medical Center · PHASE2 · withdrawn · last registry update 2023-02-02 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The P.I deceased.” | – | Registry record, Rush University Medical Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TOP2A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-01-23Phase 3 first posted: Stichting Hemato-Oncologie voor Volwassenen Nederland, Dexrazoxane + Rituximab (NCT06220032)
- 2024-01-18Phase 3 first posted: Amgen, Tarlatamab + Durvalumab (NCT06211036)
- 2024-01-03Phase 3 first posted: National Research Center for Hematology, Russia, Cyclophosphamide + Doxorubicin Hydrochloride (NCT06188676)
- 2023-12-15Phase 3 first posted: National Cancer Institute (NCI), Carboplatin + Cisplatin (NCT06172296)
- 2023-12-07Phase 3 first posted: Daiichi Sankyo, R-DXd + Paclitaxel (NCT06161025)
- 2023-11-22Phase 3 first posted: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel + Epirubicin or doxorubicin, cyclophosphamide, paclitaxel (NCT06144944)
- 2023-11-01Phase 3 first posted: AstraZeneca, Dato-DXd + Durvalumab (NCT06112379)
- 2023-10-19Phase 3 first posted: Regeneron Pharmaceuticals, Odronextamab + Rituximab (NCT06091865)
- 2023-10-19Phase 3 first posted: Regeneron Pharmaceuticals, Odronextamab + Rituximab (NCT06091254)
- 2023-10-10Phase 3 first posted: Verastem, Inc., avutometinib + Defactinib (NCT06072781)
- 2023-10-10Phase 3 first posted: Acrotech Biopharma Inc., Belinostat Injection + Pralatrexate Injection (NCT06072131)
- 2023-09-28Phase 3 first posted: National Cancer Institute (NCI), Cyclophosphamide + Doxorubicin (NCT06058377)
- 2023-09-21Phase 3 first posted: Hoffmann-La Roche, Glofitamab + Polatuzumab vedotin (NCT06047080)
- 2023-07-11Phase 3 first posted: The First Affiliated Hospital of Soochow University, Venetoclax Oral Tablet + Daunorubicin (NCT05939180)
- 2023-06-13Phase 3 first posted: Fudan University, Docetaxel + Carboplatin (NCT05901428)
- 2023-06-12Results posted on the registry: Alliance for Clinical Trials in Oncology, cisplatin + etoposide (NCT00632853)
- 2023-05-31Results posted on the registry: National Cancer Institute (NCI), Bleomycin Sulfate + Brentuximab Vedotin (NCT02166463)
- 2023-04-19Results posted on the registry: City of Hope Medical Center, Brentuximab Vedotin + Cyclophosphamide (NCT03113500)
- 2023-03-14Results posted on the registry: City of Hope Medical Center, cyclophosphamide + docetaxel (NCT00295893)
- 2023-02-24Results posted on the registry: St. Jude Children's Research Hospital, cyclophosphamide + topotecan (NCT01857934)
- 2023-01-20Phase 3 first posted: National Cancer Institute (NCI), Cabozantinib S-malate + Cisplatin (NCT05691478)
- 2023-01-09Phase 3 first posted: National Cancer Institute (NCI), Bleomycin Sulfate + Brentuximab Vedotin (NCT05675410)
- 2022-12-06Results posted on the registry: National Cancer Institute (NCI), Asparaginase + Blinatumomab (NCT02101853)
- 2022-10-13Phase 3 first posted: Genmab, Epcoritamab + Cyclophosphamide (NCT05578976)
- 2022-07-01Results posted on the registry: National Cancer Institute (NCI), Cyclophosphamide + Doxorubicin (NCT02306161)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision